These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25010298)

  • 21. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy.
    Taguchi S; Fukuhara H; Kakutani S; Takeshima Y; Miyazaki H; Suzuki M; Fujimura T; Nakagawa T; Igawa Y; Kume H; Homma Y
    Asian Pac J Cancer Prev; 2014; 15(24):10729-33. PubMed ID: 25605166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
    Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
    Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis.
    Guo L; Zhu Z; Zhang X
    Medicine (Baltimore); 2020 Mar; 99(10):e19153. PubMed ID: 32150055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
    Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
    Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy?
    Bastide C; Rossi D; Lechevallier E; Bladou F; Barriol D; Bretheau D; Grisoni V; Mancini J; Giusiano S; Eghazarian C; Van Hove A
    BJU Int; 2012 Feb; 109(4):525-30; discussion 531-2. PubMed ID: 21851534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.
    Yi Z; Li H; Li M; Hu J; Cai Z; Liu Z; Zhang C; Cheng C; He Y; Chen J; Zu X; Wang R
    World J Urol; 2024 Oct; 42(1):581. PubMed ID: 39419868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
    Hussain M; Tangen CM; Thompson IM; Swanson GP; Wood DP; Sakr W; Dawson NA; Haas NB; Flaig TW; Dorff TB; Lin DW; Crawford ED; Quinn DI; Vogelzang NJ; Glode LM
    J Clin Oncol; 2018 May; 36(15):1498-1504. PubMed ID: 29624463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
    Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.
    Choi SY; Lim B; Chi BH; Lee W; Kim JH; Kyung YS; You D; Kim CS
    Medicine (Baltimore); 2021 Aug; 100(31):e26833. PubMed ID: 34397848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
    Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
    Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
    BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.